ABOUT ACCELLTA

Board of Directors

Board of Directors

Image
Prof. (Emeritus) Peretz Lavie, Director

Prof. (Emeritus) Peretz Lavie, Director

Professor (Emeritus) Peretz Lavie - received his formal training in Sleep research and Sleep medicine at the University of Florida and at the University of California San Diego, and was a visiting professor at Harvard University in Boston. In 1975 he joined the Faculty of Medicine at the Technion - Israel Institute of Technology, where he founded the Sleep Research Laboratory and the Center for Sleep Medicine. He was the Dean of Medicine (1993-1999) and Vice President for Resource Development and External Relations (2001-2008) and for 10 years served as the President of the Technion (2009-2019). Prof. Lavie is considered one of the founders of sleep medicine. He published more than 400 scientific articles and eight books in the field of sleep research and sleep disorders. His book “The Enchanted World of Sleep" has been translated into 15 languages. His research has won many prizes, including the Elkeles Prize from the Keren Kayemet LeIsrael for the best medical scientist (2001), the University of Pisa Sleep Award to Best Sleep Researcher in Europe (2004), the American Society of Sleep Research William Gruen Prize for innovative research (2006), and the EMET prize in medicine (2006), the most prestigious prize for academic achievements in Israel. He was the founder and co-founder of 5 companies that develop and produce medical devices for sleep medicine and cardiology and provide diagnostic services.

Ms. Rona Samler, Director

Ms. Rona Samler, Director

Seasoned tech executive with an eye for great ideas, a talent for spearheading innovation and a passion for building high-growth business.
Ms. Samler serves as the Chief Business Officer of Technion Research & Development Foundation Ltd. and Managing Director of T3 - Technion Technology Transfer, Rona oversees and leads the entire commercialization spectrum and is in charge of forming and shaping commercialization vehicles and policies enabling innovations to maximize their market potential. In addition, in her capacity as CEO of AMIT- Alfred Mann Institute at the Technion Ltd., Technion's evergreen investment arm in the life science arena, Rona is in charge of AMIT's diversified investment portfolio, as well as the continuous identification of investment opportunities. 
Prior to joining the Technion's management team, Ms. Samler served as VP of Business Development at Ramot, Tel Aviv University’s technology transfer office, where she initiated and oversaw a long list of investments, licensing agreements and joint ventures with tech companies in Israel and worldwide.
Other positions held include: Head of Business Development at Syneron Medical (NASDAQ: ELOS); CEO at Cupola Medical for the Offer Brothers Group’s Naiot Venture Accelerator; VP of Global Business at Colbar LifeScience (acquired by Johnson & Johnson in 2006 for $160 million).
Ms. Samler graduated summa cum laude in Chemistry at the Technion-Israel Institute of Technology and earned her MBA at Haifa University with highest distinction.

Image
Image
Ms. Rona Samler, Director

Ms. Rona Samler, Director

Seasoned tech executive with an eye for great ideas, a talent for spearheading innovation and a passion for building high-growth business.
Ms. Samler serves as the Chief Business Officer of Technion Research & Development Foundation Ltd. and Managing Director of T3 - Technion Technology Transfer, Rona oversees and leads the entire commercialization spectrum and is in charge of forming and shaping commercialization vehicles and policies enabling innovations to maximize their market potential. In addition, in her capacity as CEO of AMIT- Alfred Mann Institute at the Technion Ltd., Technion's evergreen investment arm in the life science arena, Rona is in charge of AMIT's diversified investment portfolio, as well as the continuous identification of investment opportunities. 
Prior to joining the Technion's management team, Ms. Samler served as VP of Business Development at Ramot, Tel Aviv University’s technology transfer office, where she initiated and oversaw a long list of investments, licensing agreements and joint ventures with tech companies in Israel and worldwide.
Other positions held include: Head of Business Development at Syneron Medical (NASDAQ: ELOS); CEO at Cupola Medical for the Offer Brothers Group’s Naiot Venture Accelerator; VP of Global Business at Colbar LifeScience (acquired by Johnson & Johnson in 2006 for $160 million).
Ms. Samler graduated summa cum laude in Chemistry at the Technion-Israel Institute of Technology and earned her MBA at Haifa University with highest distinction.

Image
Mr. Patrick Zhang, Director

Mr. Patrick Zhang, Director

Patrick Zhang is an investor at Horizons Ventures, where he primarily covers biotechnology, and healthcare investments, and manages related portfolio companies for Horizons. He was trained as a chemical engineer and worked in a variety of organizations across industries including power utilities, financial services and investment management. Prior to Horizons, Patrick was an investment banker with Morgan Stanley providing financial advisory services on capital raising and cross-border M&A to his clients. Mr. Zhang received his BS degree in Chemical Engineering from UCLA and MBA from Columbia Business School.

Atlas of Human Pluripotent Stem Cells

978 1 61779 548 0

Editors:

Michal Amit, Joseph Itskovitz-Eldor

Image

Accelerating stem cell technologies

Terms of use | Privacy Policy  |  © 2021

© 2021 Accellta. All Rights Reserved. Designed By Netron Israel Ltd.

Image

Register / Login